AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04933019 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
Description: Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
Study NCT05911620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
Study NCT05911620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
Study NCT06079437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cheer
Description: Maximum isometric contraction was performed with cheering.
Study NCT06079437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The cold pressure test
Description: Maximum isometric contraction was performed with the cold pressure test.
Study NCT06503588 — intervention group
Intervention type: OTHER
Intervention: Guidelines promoting surgical abstention
Description: Guidelines promoting surgical abstention
Study NCT05630807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.
Study NCT05630807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT05832320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
Study NCT05832320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
Study NCT05425420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone hydrochloride 0.1mg/kg
Description: Single dose of methadone hydrochloride administered via intravenous (IV)
Study NCT06052774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical periodontal therapy
Description: Supra and Subgingival debridement for all patients except periodontally healthy individuals
Study NCT05379959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 125 mg of MDMA.
Study NCT05379959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of MA.
Study NCT05379959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study NCT05443997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIYCN capacity building
Description: * MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices
Study NCT05280119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchOpen ultra-portable ultrasound device
Description: Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
Study NCT05280119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device routinely used in the department.
Description: Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
Study NCT05280119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ultrasound examination by an independent referent radiologist
Description: In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
Study NCT05293275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EaseVRx Virtual Reality Headset
Description: Virtual reality device with 360 degree visualization of various scenery and interactive modules
Study NCT06572514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
Description: The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
Study NCT06573775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: treatment of myofacial trigger points with therapeutic ultrasound
Study NCT06573775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: manual massage and range of motion exercises
Study NCT06573775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: manual massage and range of motion exercises
Study NCT06573775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lidocaine phonophoresis
Description: transdermal tranmission of lidocaine molecules via ultrasound
Study NCT06573164 — intervention group
Intervention type: DRUG
Intervention: Bacillus clausii tablets（Qipian®）
Description: Take 4 tablets (0.3 mg each) orally three times daily.
Study NCT06573164 — intervention group
Intervention type: DRUG
Intervention: conventional medication
Description: Use conventional medication as needed based on the patient's condition.
Study NCT06572215 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
Study NCT06664229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall and dementia prevention exercise
Description: The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team.
Study NCT06664476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PortCare Professional Training Program
Description: The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
Study NCT06664736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
Study NCT06664736 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity
Description: The control group was advised to increase physical activity
Study NCT06663943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313 (SC)
Description: CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
Study NCT06663943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Patients in the control group receive azathioprine in combination with steroid therapy.
Study NCT06663800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ujjayi Paranayama
Description: Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
Study NCT06663800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Protocol
Description: Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
Study NCT06662981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoparative information and education
Description: The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
Study NCT06663488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural anesthesia
Description: The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
Study NCT06663488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic spinal anesthesia
Description: Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
Study NCT06661837 — intervention group
Intervention type: OTHER
Intervention: Clinical examination and mobile photo
Description: Children were both clinically examined and a mobile photo was taken for assessment
Study NCT05918952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 Antibody Test
Description: The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap.
Study NCT05918952 — intervention group
Intervention type: OTHER
Intervention: Short Clip videos
Description: Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
Study NCT05681299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone and lirglutide
Description: GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
Study NCT05681299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone
Description: GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
Study NCT05681299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
Study NCT06621121 — intervention group
Intervention type: OTHER
Intervention: Tenecteplase
Description: The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
Study NCT06621121 — intervention group
Intervention type: OTHER
Intervention: Alteplase
Description: The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
Study NCT05681299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
Study NCT05679791 — intervention group
Intervention type: DEVICE
Intervention: Dynamometer
Description: to assses hand grip
Study NCT06180993 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nirsevimab
Description: Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
Study NCT04992780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-Fractionation
Description: 62.5 Gy in 25 fractions of 2.5 Gy/fraction
Study NCT04992780 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Fractionation
Description: 60 Gy in 30 fractions of 2 Gy/fraction
Study NCT05368207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
Study NCT06000878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: first aid e-book
Description: interactive first aid e-book interventions
Study NCT06285539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib
Study NCT05239676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells
Description: The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
Study NCT06098820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Description: Four different groups will be compared with each other in terms of vitamin D effect.
Study NCT04996303 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Routine steroid administration group
Description: Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
Study NCT04996303 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Steroid pulse therapy group
Description: Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
Study NCT06358391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TS-RF Transseptal Needle
Description: Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
Study NCT06358391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRK Transseptal Needle
Description: Cross and puncture the atrial septum with the BRK Transseptal Needle
Study NCT06393192 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural analgesia (EA) only group
Description: The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
Study NCT06393192 — intervention group
Intervention type: PROCEDURE
Intervention: Quadratus lumborum block (QL2)
Description: 0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
Study NCT06393192 — intervention group
Intervention type: PROCEDURE
Intervention: Quadratus lumborum block 3(QL3)
Description: 0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
Study NCT06393192 — intervention group
Intervention type: PROCEDURE
Intervention: Quadratus lumborum block 2+3 QL(2+3)
Description: 0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
Study NCT05849402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Active aiTBS
Description: Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
Study NCT05849402 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham aiTBS
Description: Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
Study NCT05109585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
Description: evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
Study NCT05109585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
Description: evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
Study NCT05567731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrashort GnRHa
Description: the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm
Study NCT05567731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short GnRHa
Description: Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of >18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture.
Study NCT05567731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long GnRHa
Description: In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
Study NCT05784701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSCV (Full-strength)
Description: TSCV (Full-strength)